Table 1.

Changes in diabetes-related metrics in the study population from baseline to 90 days of follow-up

Diabetes-related metrics	Baseline		30 Days			60 Days			90 Days
	N	Valuesa	N	Valuesa	p value vs. baseline	N	Valuesa	p value vs. baseline	N	Valuesa	p value vs. baseline
HbA1c (%)	64	8.8 (2.2)	61	7.7 (1.6)	< 0.0001	50	6.9 (1.1)	< 0.0001	63	6.9 (1.1)	< 0.0001
Percentage of patients with HbA1c < 6.5%	64	9.4%	61	24.6%	0.0027	50	38.0%	0.0002	63	39.7%	< 0.0001
eA1c (%)	64	6.9 (2.3)	64	5.7 (1.0)	< 0.0001	64	5.8 (1.0)	0.0001	63	5.9 (1.2)	0.0007
Body Weight (kg)	64	79.0 (16.2)	64	76.1 (15.3)	< 0.0001	63	75.1 (15.0)	< 0.0001	64	74.2 (14.7)	< 0.0001
Fasting blood glucose (mg/dl)	64	151.2 (45.0)	62	135.2 (38.1)	0.0043	50	131.5 (31.9)	0.0205	62	129.1 (36.7)	0.0001
HOMA-IR	64	7.4 (3.5)	61	3.1 (2.5)	< 0.0001	50	3.3 (2.4)	< 0.0001	62	3.2 (2.8)	< 0.0001
Mean glucose from CGM (mg/dl)	64	147.4 (59.1)	64	116.7 (27.9)	< 0.0001	64	120.5 (29.6)	0.0001	64	122.6 (33.3)	0.0009
C-Peptide (ng/ml)	64	3.2 (2.2)	60	1.7 (0.9)	< 0.0001	49	2.1 (0.9)	< 0.0001	62	1.9 (0.9)	< 0.0001
Sleep (h/night)	58	5.9 (1.0)	56	6.2 (1.1)	0.1459	58	6.3 (1.2)	0.1574	59	6.1 (1.3)	0.6124
Number of steps per day	61	4677.4 (2804.9)	58	6816.8 (2854.1)	< 0.0001	60	6788.8 (3384.1)	< 0.0001	61	7004.1 (3999.0)	< 0.0001
Resting heart rate (bpm)	64	75.0 [65, 85]	62	72.5 [61, 84]	0.0001	62	71.5 [62, 85]	< 0.0001	64	71.0 [62, 85]	< 0.0001

bpm Beats per minute, CGM continuous glucose monitoring, eA1c estimated HbA1c, HbA1c hemoglobin A1c, HOMA-IR homeostatic model assessment of insulin resistance

^aValues are presented as the mean with the standard deviation (SD) in parenthesis, the percentage, or the median with the minimum–maximum values in square brackets